Drug Shortage Report for CEFUROXIME FOR INJECTION, USP
| Report ID | 160650 |
| Drug Identification Number | 02241638 |
| Brand name | CEFUROXIME FOR INJECTION, USP |
| Common or Proper name | Cefuroxime for Injection, USP 750 mg SD Vial 15 mL |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | CEFUROXIME |
| Strength(s) | 750MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 15mL |
| ATC code | J01DC |
| ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | |
| Actual start date | 2022-05-11 |
| Estimated end date | 2022-05-30 |
| Actual end date | 2022-05-30 |
| Shortage status | Resolved |
| Updated date | 2022-05-31 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a shipping delay, we will be encountering a supply interruption on our Cefuroxime for Injection, USP 750 mg SD Vial 15 mL effective today, May 11, 2022 until May 30, 2022. Our Cefuroxime for Injection, USP 1.5 g SD Vial 50 mL format is available for substitution. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2022-05-31 | English | Compare |
| v4 | 2022-05-30 | French | Compare |
| v3 | 2022-05-30 | English | Compare |
| v2 | 2022-05-15 | French | Compare |
| v1 | 2022-05-15 | English | Compare |
Showing 1 to 5 of 5